Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Summary Background We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Methods Previously untreated patients with EGFR mutation-positive stage IIIB or IV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2015-02, Vol.16 (2), p.141-151
Hauptverfasser: Yang, James Chih-Hsin, Prof, Wu, Yi-Long, Prof, Schuler, Martin, Prof, Sebastian, Martin, MD, Popat, Sanjay, FRCP, Yamamoto, Nobuyuki, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, O'Byrne, Kenneth, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Geater, Sarayut L, MD, Lee, Kye Young, Prof, Tsai, Chun-Ming, Prof, Gorbunova, Vera, Prof, Hirsh, Vera, Prof, Bennouna, Jaafar, Prof, Orlov, Sergey, Prof, Mok, Tony, Prof, Boyer, Michael, Prof, Su, Wu-Chou, Prof, Lee, Ki Hyeong, Prof, Kato, Terufumi, MD, Massey, Dan, MSc, Shahidi, Mehdi, MD, Zazulina, Victoria, MD, Sequist, Lecia V, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!